Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Andrew Gengos currently holds 137,500 shares of ImmunoCellular Therapeutics, Ltd. (IMUC), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Andrew Gengos has been a net buyer of IMUC stock. They have purchased $300.7K and sold $7.8K worth of shares.
Andrew Gengos's most recent insider trade was on Jan 14, 2026, when they sold 137,500 shares at $0.00 per share.
Andrew Gengos serves as Executive at ImmunoCellular Therapeutics, Ltd. (IMUC). They have executed 28 insider transactions totaling $308.5K over their tenure at the company.
Andrew Gengos holds the position of Executive at ImmunoCellular Therapeutics, Ltd., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 12 years and currently hold a stake valued at $0.
Andrew Gengos has shown a buying trading pattern, with $300.7K in total purchases and $7.8K in total sales across all transactions. Their most recent activity indicates a tendency to accumulate shares.
The largest transaction by Andrew Gengos was on Jun 5, 2023, when they purchased $45.0K worth of ATHA shares. This transaction involved 15,000 shares at $3.00 per share.
Andrew Gengos currently owns 137,500 shares of ImmunoCellular Therapeutics, Ltd. (IMUC), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Andrew Gengos's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Andrew Gengos has 28 Form 4 filings on record as an insider at ImmunoCellular Therapeutics, Ltd..
Set alerts for Andrew Gengos and 40,000+ other insiders.